Cancer discovery news

Our researchers are making the discoveries that defeat cancer. Read the latest findings from our world-leading research.

Visit our main news hub to read about news on new funding, our fundraising activities and much more. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.

If you’re a journalist and want to find out more, you can contact our media relations team.

futuristic view through looking up at building through fountain 547x410
Tumour-liquifying microbubbles and immune cell tracking: UK’s first convergence science centre officially launches

29/07/19

Two of the UK’s foremost academic research institutions, The Institute of Cancer Research, London, and Imperial College London, are coming together with funding from Cancer Research UK to launch the new £13 million Convergence Science Centre.
olaparib_547x410
ICR calls for wider gene testing in ovarian cancer after approval of olaparib earlier in treatment for women with BRCA mutations

26/07/19

The ICR responds to the approval by NHS regulators NICE for the use of targeted cancer drug olaparib earlier in the course of treatment for women with late-stage ovarian cancer and other gynaecological cancers who have BRCA gene mutations.
prostate cancer cell
Gene test picks out prostate cancers patients who could benefit from ‘search-and-destroy’ medicine

23/07/19

Testing for genetic weaknesses in repairing DNA could pick out men who may benefit from a new type of targeted nuclear medicine, a new study reports.
A brain model
Discovery Club shows the power of new research in the patient journey

19/07/19

Members of the The Discovery Club gathered at the Royal Society of Chemistry last month to learn how our research is influencing the cancer patient journey.
Breast cancer cell
Cancer trades in sugar for fatty acids in order to spread around the body

18/07/19

Scientists have uncovered a crucial change in cancer cells that allows them to spread around the body – by switching from sugar to fatty acids to fuel their growth.
ICR Logo
UK cancer treatment ‘revolution’ as survey finds third of patients receiving modern precision treatments

16/07/19

Over one-third of surviving cancer patients have received state-of-the-art targeted drug treatment or immunotherapy, reveals a new survey highlighting the ‘revolution’ in cancer treatment over the last decade.
Metastatic breast cancer cells in pleural fluid
Pairing targeted drugs for breast and lung cancer could overcome treatment resistance

12/07/19

Targeted drugs for breast and lung cancer could be used together to overcome resistance to treatment in several different tumour types, a new study shows.
Dan Lloyd and Isla Furlong
ICR alumni return to inspire the next generation at the 2019 Student Conference

09/07/19

At The Institute of Cancer Research’s annual Student Conference, our PhD students had the opportunity to meet with ICR alumni and find out more about their career journeys.
Scanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit: NIAID
Immunotherapy could work against bowel cancers resistant to important targeted treatment

08/07/19

Patients with bowel cancer who have stopped responding to a widely used targeted drug could benefit from immunotherapy, a major new study reveals.
ICR Logo
ICR recognises next generation of cancer researchers

05/07/19

A new generation of cancer researchers took to the stage at London’s Guildhall this week as The Institute of Cancer Research, London, held its annual awards ceremony.
Professor Sangeeta Bhatia
ICR honours campaigning parents and convergence scientist with honorary degrees

05/07/19

The ICR has awarded the founders of the children’s cancer charity Christopher’s Smile and a world-leading expert in convergence science with honorary degrees at this year’s awards ceremony.
Pills or drugs in blister pack
Response to gene-targeted drugs depends on cancer type

01/07/19

Cancers with the same genetic weaknesses respond differently to targeted drugs depending on the tumour type of the patient, new research reveals.